Limited time75% off all plans
Get the app

Principles of Pediatric Chemotherapy

Principles of Pediatric Chemotherapy

Principles of Pediatric Chemotherapy

On this page

Principles of Pediatric Chemotherapy - Tiny Patients, Big Differences

  • Pediatric physiology alters drug ADME (Absorption, Distribution, Metabolism, Excretion).
  • Dosing: Primarily Body Surface Area (BSA) based ($mg/m^2$).
    • Carboplatin: Calvert formula (Dose = Target AUC x (GFR + 25)).
  • Generally higher chemo tolerance & tumor sensitivity vs. adults.
  • Key focus: Minimizing long-term effects (growth, neurocognitive, fertility, secondary cancers).
  • Aggressive supportive care vital (hydration, antiemetics, G-CSF).
  • Multidisciplinary team (MDT) approach is crucial.

⭐ Pediatric cancers often show higher cure rates (e.g., ALL >80-90%) and better tolerance to intensive chemotherapy than adult cancers, but have a unique malignancy spectrum and long-term sequelae.

Principles of Pediatric Chemotherapy - Little Heroes' Weapons

  • Pediatric cancers often highly chemosensitive. Goal: Cure with minimal long-term effects.
  • Targets rapidly dividing cells. Combination regimens are standard.
  • Key principles: cell cycle specificity, dose intensity, minimizing toxicity.
  • 📌 Cell Cycle: M-phase (Vinca), S-phase (Antimetabolites, Etoposide), G2 (Bleomycin). Non-specific: Alkylating, Anthracyclines.

Chemotherapy drug classes and cell cycle targets

Drug ClassMoAExamplesUsesToxicities
Alkylating AgentsCross-link DNACyclophosphamideLeukemias, lymphomas, solid tumorsMyelosuppression, hemorrhagic cystitis, 2° Malign
AntimetabolitesBlock DNA/RNA synthesisMethotrexate, 6-MPLeukemias (ALL), lymphomasMyelosuppression, mucositis, hepatotoxicity
AnthracyclinesDNA intercalation, Topo II inh., radicalsDoxorubicinLeukemias, lymphomas, sarcomas, WilmsCardiotoxicity (cumulative), myelosuppression
Vinca AlkaloidsInhibit microtubule assembly (M-phase)VincristineLeukemias, lymphomas, solid tumorsNeurotoxicity, constipation, BM sparing

Principles of Pediatric Chemotherapy - Side Effect Battles

Chemotherapy targets rapidly dividing cells, affecting cancer and healthy tissues. Managing side effects is vital.

  • Acute: Myelosuppression, nausea/vomiting, mucositis.
  • Organ-Specific: Cardiac, renal, neurotoxicity.
  • Long-Term: Growth issues, secondary cancers, infertility.

Key Side Effects & Management:

System/ToxicityKey DrugsPeds NotesManagement Highlights
MyelosuppressionMost chemoANC < 500/µL criticalG-CSF, transfusions
Nausea/VomitingCisplatin, DoxoHigh anticipatoryOndansetron, Aprepitant
MucositisMTX, 5-FUPain, poor nutritionHygiene, cryotherapy
Hemorrhagic CystitisCyclophos, IfosAcrolein toxicityMesna, hydration
CardiotoxicityAnthracyclinesCumulative doseDexrazoxane, LVEF monitoring
NeurotoxicityVincristine, CisplatinFoot drop (V), Ototoxic (Cis) 📌 CisPLATinDose adjust
NephrotoxicityCisplatin, MTXMonitor GFRHydration, Leucovorin (MTX)
Tumor Lysis (TLS)ALL, Burkitt'sMetabolic emergencyRasburicase, hydration

Chemotherapy side effects by organ system

Management of Febrile Neutropenia:

Principles of Pediatric Chemotherapy - Dose & Future Watch

  • Dosing:
    • Primarily Body Surface Area (BSA): $\text{BSA (m}^2\text{) = } \sqrt{(\text{Height (cm)} \times \text{Weight (kg)}) / 3600}$.
    • Carboplatin: Calvert formula $\text{Dose (mg) = Target AUC} \times \text{(GFR + 25)}$.
    • Age/weight bands for infants.
  • Pediatric Pharmacokinetics:
    • ↑ GFR, ↑ metabolism (MTX, cyclophosphamide).
    • Larger Vd (water-soluble drugs), ↓ protein binding.
  • Future Watch (Late Effects):
    • Secondary malignancies (e.g., AML post-etoposide).
    • Organ toxicities: cardiac (anthracyclines), pulmonary (bleomycin), renal (cisplatin), neuro (vincristine).
    • Endocrine: growth issues, infertility.
    • Long-term surveillance crucial.

⭐ Anthracyclines (e.g., Doxorubicin) cause dose-dependent cardiotoxicity, potentially years later, requiring long-term cardiac follow-up.

High‑Yield Points - ⚡ Biggest Takeaways

  • BSA-based dosing is standard for most pediatric chemotherapy.
  • Children exhibit higher chemosensitivity due to rapid cell proliferation.
  • Altered PK/PD in children significantly impacts drug efficacy and toxicity.
  • Long-term sequelae, including secondary malignancies and organ damage, are critical.
  • Sanctuary sites (CNS, testes) often require specific therapeutic approaches.
  • Aggressive supportive care is vital for managing treatment toxicities.
  • Pediatric cancers show a unique spectrum (leukemias, lymphomas, embryonal tumors).

Continue reading on Oncourse

Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.

CONTINUE READING — FREE

or get the app

Rezzy — Oncourse's AI Study Mate

Have doubts about this lesson?

Ask Rezzy, your AI Study Mate, to explain anything you didn't understand

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

START FOR FREE